For more than a decade, China has been the top choice for U.S. pharmaceutical companies outsourcing drug development chemistry due to its low labour costs, sophisticated infrastructure, and a large pool of skilled chemists.
However, the growing prominence of Contract Development and Manufacturing Organizations (CDMOs) in India is changing the trend. Indian companies have long had the essential elements needed for a successful CDMO business, building on their significant roles in preclinical drug discovery and as global suppliers of both finished generic drugs and active pharmaceutical ingredients (APIs).
Research by India Ratings and Research indicates that U.S. pharmaceutical firms are expected to increase their orders from Indian CDMOs and drug discovery service providers over the next eighteen months.
The anticipated growth is in response to the potential enactment of the Biosecure Act. As reported by cen.acs.org, the research firm’s analysis of fifteen Indian companies reveals that over sixty percent have experienced a surge in new business inquiries since the introduction of the bill.
